These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35285786)

  • 21. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
    Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
    Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
    Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects.
    Gorycki P; Magee M; Ackerman P; Miao X; Moore K
    Xenobiotica; 2022 Jun; 52(6):541-554. PubMed ID: 36083110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fostemsavir: First Approval.
    Markham A
    Drugs; 2020 Sep; 80(14):1485-1490. PubMed ID: 32852743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).
    McGowan IM; Chawki S; Hendrix CW; Anton PA; Marzinke MA; Brand RM; Engstrom JC; Rohan LC; Abebe KZ; Richardson-Harman N; Siegel A; Reinhart A; Steytler J; Stall R; Spiegel H; Chen B; Achilles SL; Jacobson CE; Khanukova E; Cranston RD
    AIDS Res Hum Retroviruses; 2022 Apr; 38(4):269-278. PubMed ID: 34384282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir.
    Heidary M; Shariati S; Nourigheimasi S; Khorami M; Moradi M; Motahar M; Bahrami P; Akrami S; Kaviar VH
    BMC Infect Dis; 2024 Feb; 24(1):250. PubMed ID: 38395761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.
    Muccini C; Canetti D; Castagna A; Spagnuolo V
    Drug Des Devel Ther; 2022; 16():297-304. PubMed ID: 35115764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
    Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M
    Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection.
    Hiryak K; Koren DE
    Ann Pharmacother; 2021 Jun; 55(6):792-797. PubMed ID: 32964736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir.
    Meanwell NA; Krystal MR; Nowicka-Sans B; Langley DR; Conlon DA; Eastgate MD; Grasela DM; Timmins P; Wang T; Kadow JF
    J Med Chem; 2018 Jan; 61(1):62-80. PubMed ID: 29271653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating fostemsavir as a therapeutic option for patients with HIV.
    Berruti M; Pincino R; Taramasso L; Di Biagio A
    Expert Opin Pharmacother; 2021 Aug; 22(12):1539-1545. PubMed ID: 34125644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fostemsavir for the treatment of HIV.
    Seval N; Frank C; Kozal M
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):961-966. PubMed ID: 33331202
    [No Abstract]   [Full Text] [Related]  

  • 38. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
    Llibre JM; Aberg JA; Walmsley S; Velez J; Zala C; Crabtree Ramírez B; Shepherd B; Shah R; Clark A; Tenorio AR; Pierce A; Du F; Li B; Wang M; Chabria S; Warwick-Sanders M
    Front Immunol; 2024; 15():1394644. PubMed ID: 38863717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
    Wang T; Ueda Y; Zhang Z; Yin Z; Matiskella J; Pearce BC; Yang Z; Zheng M; Parker DD; Yamanaka GA; Gong YF; Ho HT; Colonno RJ; Langley DR; Lin PF; Meanwell NA; Kadow JF
    J Med Chem; 2018 Jul; 61(14):6308-6327. PubMed ID: 29920093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.